studies

More documents

Recommendations

Info

1374A CATEGORY INDEX HEPATOLOGY, October, 2015 Concerted effects of the two 1429 Correlations between hepatic 1428 Evaluation of EASL recommend 117 Host microbiota dictates the 1427 How gold is the “gold stan 1443 Innate Lymphoid Cell (ILC) S 1430 Lysyl oxidase-like-2 (LOXL2) 1442 PEGylated TRAIL treatment am 115 Reproductive Aging, Independ 1444 Risk of cirrhosis in first d 1431 Serum lysyl oxidase-like-2 ( 1435 Serum wisteria floribunda ag 1446 Statins, ACE inhibitors and 116 Systemic administration of a 118 The epidemiology of cirrhosi 1424 Treatment of Hepatic Fibrosi 1423 A marker of true type III co 1432 A novel canine liver cirrhos 1447 A novel glycobiomarker, Wist 1448 Antifibrotic efficacy of a T 1434 Comparing the liver stiffnes 1441 Fibrosis is not just fibrosi 119 Hepatitis C treatment and Pr 1450 In vivo cell specific gene s 1426 In vivo reprogramming of myo 98 New Prognostic Model for 1-y 1438 Novel assessment of hepatic 1425 Safety, Pharmacokinetics, an 1433 Second harmonic generation m 1449 Liver Transplantation and Liver Surgery LO1. Cellular Immunobiology, Preservation, and Cell Transplantation Autologous hepatocyte transp 2 Blockade of RIP kinase pathw 12 Delayed Donor Bone Marrow In 54 Identification of microRNAs 341 Novel Vasodilator and Anti-i 340 Previous ischemic preconditi 342 Extracellular vesicles from 335 Liver Fabrication Using Dece 336 Promotion of liver transplan 338 The innate immune cell micro 339 Three-dimensional bioactive 337 LO2. Donor and Allocation Issues, Living Donor and Split Liver Transplantation, and Hepatobiliary Surgery 3D Printed Liver Models for 840 A Failure of the Model of En 849 A Novel Percutaneous Organ P 216 Application of Gadoxetate Di 869 Auxiliary partial orthotopic 867 Clinical impact of 18F-FDG-P 862 Comparison of Liver Transpla 49 Controlled attenuation param 876 Functional Status Predicts P 845 Impact of UNOS Imaging Crite 10 Liver Transplant Outcomes an 69 Liver transplantation waitin 68 Living donor liver transplan 860 Living or Deceased Donor Liv 863 Mechanisms of Gender Dispari 865 Natural history of liver tra 873 Older Liver Transplant (LT) 844 Outcomes of Patients Undergo 854 Physical function predicts l 841 Recanalization of complete a 846 Safety of live liver donatio 859 The impact of non-identical 72 Obesity is predictive of 839 A shift to the left: A compa 838 Association of Pre-Transplan 855 Comparable Short And Long Te 70 Coronary Angiography in Pati 874 Could Share 35 disadvantage 6 Effective and Safe postopera 71 External Validation of a US- 853 Graft Survival following Dom 868 Interactive Effect Of Donor 878 Lack of Radiologic-Pathologi 870 Long Term Survival Of Liver 875 Longer Term Efficacy of Simu 836 Low serum testosterone predi 842 Novel Sonar Guided Technique 858 Objective Measurement of Kar 850 PALBI-An Objective Score Bas 851 Patient Safety in Living Don 847 Predicting Futility of Liver 856 Prediction of waitlist morta 9 Predictors of Retransplantat 877 Preliminary Data Analysis fr 837 Region-Based Projections of 67 Remnant Liver Ischemia Is As 857 Significance of functional h 866 The effect of recipient and 848 The transportable machine pe 215 Third Liver Transplantation 864 Tool for efficient and effec 843 Traveling for a Liver Transp 872 Traveling for a Liver Transp 861 Treatment with Optifast Redu 11 Using Biomarkers to Predict 871 Wait Times of 18 Mon 50 “Oldest Old” (≥80 year 852 LO3. Immunosuppression, Outcomes, and Complications 15 first-days over-immunosup 1251 Females, Hispanics, and Nona 1252 A New Score based on explant 1232 Aging of liver transplant re 1211 Are cirrhotic patients await 1239 Coffee consumption promotes 1222 Comparative analysis of rena 1233 Conversion from Sirolimus to 1247 Downstaging or Bridging Ther 1262 Early Cytomegalovirus infect 1268 Early Liver Transplantation 1215 Everolimus is Associated wit 1226 Glycine is graft protective 1227 Good results of liver transp 1269 How intra-operative factors 1271 IgG4 status in explanted liv 1246 Impact of Positive Crossmatc 1254 Lack of effect of CMV reacti 1230 Liver Transplant (LT) Candid 1259 Liver Transplantation For Al 1250 MELD Based Outcomes of Simul 1249 Metabolic Syndrome and Insul 1270 Minimal hepatic encephalopat 51 Morbid Obesity and Diabetes 1273 Neurological Syndrome de nov 1256 Outcomes of Transjugular Int 1280 Post-Transplant Lymphoprolif 1275 Pre-Transplant Sarcopenia Do 1267 Pre-transplant portal vein t 1258 Prediction of Posthepatectom 1213 Recipient Risk Factors for A 1266 Reduced Survival in Elderly 1208 Reevaluating Risk Factors fo 1241 Renal Function Improvement i 1281 Renal function at month 1 an 1237 Reporting Physical Function 1219 Retained HLA Class II Donor 1236 Risk Stratification for Opti 1277 Role of Coronary Artery Calc 1255 Rotational Thromboelastometr 1260 Sarcopenia is a Risk Factor 1276 Severity and Predictive Fact 1264 Sublingual administration of 1217 Synergistic anticancer effec 1278 Systolic Dysfunction Post-Li 1261 The Association of Pre-Trans 1242 The Combination of Strongly 1228 The Small Molecule TLR9 Anta 1209 Two-Year Results of a Pilot 1214 Ursodeoxycholic Acid as Adju 1224 Outcomes Post-Liver 1243 A Multi-Center Study to Deve 53 A Multi-center Study on Down 4 Acute Kidney Injury among Pa 1220 Assessment of Energy Metabol 1235 Blood Phosphatidyl ethanol i 1231 Echocardiography for Liver T 1257 Effective Systems of Care Im 1272 Evaluation of risk indices t 1279 Incidence of Acute Cellular 5 Increase in Red Cell Distrib 1240 Intrahepatic Cholangiocarcin 1274 Liver Transplantation for Po 1216 Liver Transplantation in Old 1245 Long-Term Outcome of Extrahe 1234 Ohio Solid Organ Transplanta 1265 Outcomes of Patients with Fa 1263 Outcomes of acute-on-chronic 1212 Physical activity measured b 1248 Pre-transplant echocardiogra 1218 Primary Biliary Cirrhosis: N 1210 Quantiferon-CMV testing afte 1225 Recipient obesity is an inde 1223 Renal Function Recovery and 1253 Renal Recovery Outcomes afte 1221 The Functional Basis for Cog 52 The Gap Between Assessed Phy 1244 The coming of age of the gra 1229 Value of Magnetic Resonance 1238 LO4. Viral Hepatitis Detectable HBVDNA in liver a 1739 Determinants and impact of e 3 Effect of simeprevir adminis 1754 HBV cccDNA evaluation in HBV 1740 Hepatitis E infection in imm 1752 Impact of Sofosbuvir-Based R 204 Liver Cancer in Patients Cur 1742 Prevention of Recurrent Hepa 200 Prevention of post-transplan 1751
HEPATOLOGY, VOLUME 62, NUMBER 1 (SUPPL) CATEGORY INDEX 1375A The effect of ledipasvir/sof 1741 Two Combined Genetic Markers 1 An Evidence-Based Algorithm 1745 Curing Decompensated Wait Li 202 Current Trends in Liver Tran 199 Effects of pre-transplant he 1749 HCV Infection in Aging Baby 201 Long-term Outcome of Entecav 1746 Long-term complete prophylax 203 Long-term outcomes after hep 1748 Oral Interferon-free Antivir 1753 Protective Birth Cohort Effe 1750 Renal safety of nucleos(t)id 1744 Treating HCV patients on the 1743 Metabolic and Genetic Disease MO1. Hemochromatosis, Wilson Disease, and a-1 Antitrypsin Deficiency UGT1A regulation by a member 2108 Accumulation of hepatitis B 2115 Association between Psoas Mu 2110 Clinical features, biochemic 2106 Congenital glycosylation def 2102 Dicer-Substrate Small RNAs a 2116 Liver-specific deletion of t 197 Mutational analysis of ATP7B 2107 Pitfalls in Erythrocyte Prot 2111 Variation in erythrocyte and 2112 A Nationwide, Population-bas 2113 Cardiac MRI for Assessment o 2104 Combining high-throughput ge 193 Functional analysis and drug 2103 GNPAT Variant D519G in patie 2117 Genetic variants associated 2105 Hepatocellular Carcinoma in 2101 Liver Fibrosis is Present in 138 Relapse of Porphyria Cutanea 2100 Relapse of porphyria cutanea 2114 The real world experience of 2099 Wilson disease: gestational 2109 Midlevel Professionals (nurses, nurse practitioners, etc.) NO1. Behavioral and Quality Issues Interferon (IFN), Ribavirin 315 TNF-alpha is the Most Consis 316 Longitudinal alteration in h 314 Monitoring Pruritus for Pati 317 The Need for Improved Liver 313 Uncertainty and Hepatitis C: 318 NO2. Practice Issues Significant non–adherence 646 Hepatology nursing in Canada 647 Pharmacists mitigate effect 648 Pediatric Hepatology OO1. Pediatric Liver Disease - Basic Science A novel mouse model for the 2098 Enteral Obeticholic Acid Pre 194 Enteral Obeticholic Acid Pro 1689 Hepatic macrophage IL-1 beta 1687 Molecular mechanism of IL-1 1688 OO2. Biliary Atresia and Cholestasis B cell activation in the rot 1699 Biliatresone causes GSH redu 195 C5aR targets immune and epit 1698 Exome Sequencing and de novo 1693 Prophylactic endoscopic trea 134 Role of transient elastograp 1697 DXA Bone Density in Alagille 1694 Diagnostic determination sys 1696 Expansion of regulatory T ce 1695 Human iPSC-derived hepatocyt 1690 King’s-Variceal Prediction 1691 Molecular genetic dissection 135 Neurodevelopmental Outcomes 133 The Rotavirus Induced Mouse 1692 OO3. Viral and Autoimmune Hepatitis Autoimmune Liver disease in 1711 Dissecting cellular entry me 1703 Prediction of nucleotide ana 1700 Quantitative Maternal Hepati 1701 The Impact of Hepatitis B Va 1705 Validation of transient elas 136 “Hepatic Granulomas: 18 Ye 1712 CD4+ helper T Cell Dysregula 1706 Differentiating autoimmune h 1713 HCV infection shifts CD8+ T 1708 Long-term follow up of child 1710 Pharmacokinetics of Once Dai 1707 Pre-core region mutations an 1704 Predictors of poor outcome i 1702 The Natural History of Autoi 1709 OO4. Metabolic and Genetic Diseases NOTCH2 variants in cholestat 1721 A functional classification 196 Congenital Lactic acidemia ( 1725 Liver Involvement in Turnerâ 1720 Autosomal Recessive Polycyst 1718 Bile acid metabolism is alte 1726 Hepatic Manifestations in Ad 1717 Liver Disease in Subjects wi 1722 Nocturnal Hypoxia is associa 1715 Primary immunodeficiencies i 1723 Recurrent recessive mutation 1719 Risk Factors Associated with 1716 Screening for Mitochondrial 1714 Zinc monotherapy for young p 1724 OO5. Pediatric Liver Transplantation AST-to-platelet ratio index 1733 Epidemiology and outcomes of 1737 Preformed and de novo DSA ar 1735 Serum autoantibodies are ass 1728 Surveillance biopsies in ped 1736 Immunization Practic 1738 Distance Affects Mortality o 1732 Dynamics of pediatric liver 1734 Hospitalizations for Respira 137 Pediatric liver transplant r 1730 Pre-transplant mortality ris 1727 Racial and ethnic variations 1729 Regulatory T cells in de nov 1731 Portal Hypertension and Other Complications of Cirrhosis PO1. Experimental Adipose Tissue-Specific ATGL 1531 Diabetes is Associated with 1527 ELF and Angiopoietins acc 1530 Elevated galectin-3 in cirrh 1529 Enoxaparin treatment does no 1520 Hepatocyte Tissue Factor Con 81 Inflammation and hypoxia reg 1519 L-carnitine prevents ammonia 1528 Liver NK cells from NLG4-/- 1532 Long term oral treatment of 1523 Neuro-inflammation in Cirrho 1521 Portal tract fibrosis is ind 1526 Simvastatin prevents the agg 1518 Statins activate the canonic 80 Taurine lowers portal pressu 149 The Evaluation of Portal Hyp 1524 The effects of apoptosis inh 79 Ammonia Produces Pathologica 1517 Emricasan, a pan caspase inh 1522 The soluble guanylyl cyclase 1525 Usefulness of spleen stiffne 1533 PO2. Ascites, Renal Dysfunction, and Hepatorenal Syndrome Acute Kidney Injury definiti 266 Acute Kidney Injury in criti 275 Acute kidney injury in cirrh 288 Chronic Rifaximin Therapy De 271 Clinical Utilization of Seru 280 Coronary microvascular dysfu 268 Deleterious effect of beta-b 265 Diagnostic accuracy of the P 264 Disturbance in diurnal renal 267 Effect of Beta-Blockers on S 282 Is Midodrine, Octreotide, an 286 Midodrine and Tolvaptan in P 259 Multicenter retrospective an 281 New score CyBAC-Del incorpor 262 Organ Failures Associated Wi 83 Predictive factors for a goo 296
Page 2 and 3:
208A AASLD ABSTRACTS HEPATOLOGY, Oc
Page 4 and 5:
Page 6 and 7:
Page 8 and 9:
Page 10 and 11:
Page 12 and 13:
Page 14 and 15:
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
Page 262 and 263:
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
Page 270 and 271:
Page 272 and 273:
Page 274 and 275:
Page 276 and 277:
Page 278 and 279:
Page 280 and 281:
Page 282 and 283:
Page 284 and 285:
Page 286 and 287:
Page 288 and 289:
Page 290 and 291:
Page 292 and 293:
Page 294 and 295:
Page 296 and 297:
Page 298 and 299:
Page 300 and 301:
Page 302 and 303:
Page 304 and 305:
Page 306 and 307:
Page 308 and 309:
Page 310 and 311:
Page 312 and 313:
Page 314 and 315:
Page 316 and 317:
Page 318 and 319:
Page 320 and 321:
Page 322 and 323:
Page 324 and 325:
Page 326 and 327:
Page 328 and 329:
Page 330 and 331:
Page 332 and 333:
Page 334 and 335:
Page 336 and 337:
Page 338 and 339:
Page 340 and 341:
Page 342 and 343:
Page 344 and 345:
Page 346 and 347:
Page 348 and 349:
Page 350 and 351:
Page 352 and 353:
Page 354 and 355:
Page 356 and 357:
Page 358 and 359:
Page 360 and 361:
Page 362 and 363:
Page 364 and 365:
Page 366 and 367:
Page 368 and 369:
Page 370 and 371:
Page 372 and 373:
Page 374 and 375:
Page 376 and 377:
Page 378 and 379:
Page 380 and 381:
Page 382 and 383:
Page 384 and 385:
Page 386 and 387:
Page 388 and 389:
Page 390 and 391:
Page 392 and 393:
Page 394 and 395:
Page 396 and 397:
Page 398 and 399:
Page 400 and 401:
Page 402 and 403:
Page 404 and 405:
Page 406 and 407:
Page 408 and 409:
Page 410 and 411:
Page 412 and 413:
Page 414 and 415:
Page 416 and 417:
Page 418 and 419:
Page 420 and 421:
Page 422 and 423:
Page 424 and 425:
Page 426 and 427:
Page 428 and 429:
Page 430 and 431:
Page 432 and 433:
Page 434 and 435:
Page 436 and 437:
Page 438 and 439:
Page 440 and 441:
Page 442 and 443:
Page 444 and 445:
Page 446 and 447:
Page 448 and 449:
Page 450 and 451:
Page 452 and 453:
Page 454 and 455:
Page 456 and 457:
Page 458 and 459:
Page 460 and 461:
Page 462 and 463:
Page 464 and 465:
Page 466 and 467:
Page 468 and 469:
Page 470 and 471:
Page 472 and 473:
Page 474 and 475:
Page 476 and 477:
Page 478 and 479:
Page 480 and 481:
Page 482 and 483:
Page 484 and 485:
Page 486 and 487:
Page 488 and 489:
Page 490 and 491:
Page 492 and 493:
Page 494 and 495:
Page 496 and 497:
Page 498 and 499:
Page 500 and 501:
Page 502 and 503:
Page 504 and 505:
Page 506 and 507:
Page 508 and 509:
Page 510 and 511:
Page 512 and 513:
Page 514 and 515:
Page 516 and 517:
Page 518 and 519:
Page 520 and 521:
Page 522 and 523:
Page 524 and 525:
Page 526 and 527:
Page 528 and 529:
Page 530 and 531:
Page 532 and 533:
Page 534 and 535:
Page 536 and 537:
Page 538 and 539:
Page 540 and 541:
Page 542 and 543:
Page 544 and 545:
Page 546 and 547:
Page 548 and 549:
Page 550 and 551:
Page 552 and 553:
Page 554 and 555:
Page 556 and 557:
Page 558 and 559:
Page 560 and 561:
Page 562 and 563:
Page 564 and 565:
Page 566 and 567:
Page 568 and 569:
Page 570 and 571:
Page 572 and 573:
Page 574 and 575:
Page 576 and 577:
Page 578 and 579:
Page 580 and 581:
Page 582 and 583:
Page 584 and 585:
Page 586 and 587:
Page 588 and 589:
Page 590 and 591:
Page 592 and 593:
Page 594 and 595:
Page 596 and 597:
Page 598 and 599:
Page 600 and 601:
Page 602 and 603:
Page 604 and 605:
Page 606 and 607:
Page 608 and 609:
Page 610 and 611:
Page 612 and 613:
Page 614 and 615:
Page 616 and 617:
Page 618 and 619:
Page 620 and 621:
Page 622 and 623:
Page 624 and 625:
Page 626 and 627:
Page 628 and 629:
Page 630 and 631:
Page 632 and 633:
Page 634 and 635:
Page 636 and 637:
Page 638 and 639:
Page 640 and 641:
Page 642 and 643:
Page 644 and 645:
Page 646 and 647:
Page 648 and 649:
Page 650 and 651:
Page 652 and 653:
Page 654 and 655:
Page 656 and 657:
Page 658 and 659:
Page 660 and 661:
Page 662 and 663:
Page 664 and 665:
Page 666 and 667:
Page 668 and 669:
Page 670 and 671:
Page 672 and 673:
Page 674 and 675:
Page 676 and 677:
Page 678 and 679:
Page 680 and 681:
Page 682 and 683:
Page 684 and 685:
Page 686 and 687:
Page 688 and 689:
Page 690 and 691:
Page 692 and 693:
Page 694 and 695:
Page 696 and 697:
Page 698 and 699:
Page 700 and 701:
Page 702 and 703:
Page 704 and 705:
Page 706 and 707:
Page 708 and 709:
Page 710 and 711:
Page 712 and 713:
Page 714 and 715:
Page 716 and 717:
Page 718 and 719:
Page 720 and 721:
Page 722 and 723:
Page 724 and 725:
Page 726 and 727:
Page 728 and 729:
Page 730 and 731:
Page 732 and 733:
Page 734 and 735:
Page 736 and 737:
Page 738 and 739:
Page 740 and 741:
Page 742 and 743:
Page 744 and 745:
Page 746 and 747:
Page 748 and 749:
Page 750 and 751:
Page 752 and 753:
Page 754 and 755:
Page 756 and 757:
Page 758 and 759:
Page 760 and 761:
Page 762 and 763:
Page 764 and 765:
Page 766 and 767:
Page 768 and 769:
Page 770 and 771:
Page 772 and 773:
Page 774 and 775:
Page 776 and 777:
Page 778 and 779:
Page 780 and 781:
Page 782 and 783:
Page 784 and 785:
Page 786 and 787:
Page 788 and 789:
Page 790 and 791:
Page 792 and 793:
Page 794 and 795:
1000A AASLD ABSTRACTS HEPATOLOGY, O
Page 796 and 797:
Page 798 and 799:
Page 800 and 801:
Page 802 and 803:
Page 804 and 805:
Page 806 and 807:
Page 808 and 809:
Page 810 and 811:
Page 812 and 813:
Page 814 and 815:
Page 816 and 817:
Page 818 and 819:
Page 820 and 821:
Page 822 and 823:
Page 824 and 825:
Page 826 and 827:
Page 828 and 829:
Page 830 and 831:
Page 832 and 833:
Page 834 and 835:
Page 836 and 837:
Page 838 and 839:
Page 840 and 841:
Page 842 and 843:
Page 844 and 845:
Page 846 and 847:
Page 848 and 849:
Page 850 and 851:
Page 852 and 853:
Page 854 and 855:
Page 856 and 857:
Page 858 and 859:
Page 860 and 861:
Page 862 and 863:
Page 864 and 865:
Page 866 and 867:
Page 868 and 869:
Page 870 and 871:
Page 872 and 873:
Page 874 and 875:
Page 876 and 877:
Page 878 and 879:
Page 880 and 881:
Page 882 and 883:
Page 884 and 885:
Page 886 and 887:
Page 888 and 889:
Page 890 and 891:
Page 892 and 893:
Page 894 and 895:
Page 896 and 897:
Page 898 and 899:
Page 900 and 901:
Page 902 and 903:
Page 904 and 905:
Page 906 and 907:
Page 908 and 909:
Page 910 and 911:
Page 912 and 913:
Page 914 and 915:
Page 916 and 917:
Page 918 and 919:
Page 920 and 921:
Page 922 and 923:
Page 924 and 925:
Page 926 and 927:
Page 928 and 929:
Page 930 and 931:
Page 932 and 933:
Page 934 and 935:
Page 936 and 937:
Page 938 and 939:
Page 940 and 941:
Page 942 and 943:
Page 944 and 945:
Page 946 and 947:
Page 948 and 949:
Page 950 and 951:
Page 952 and 953:
Page 954 and 955:
Page 956 and 957:
Page 958 and 959:
Page 960 and 961:
Page 962 and 963:
Page 964 and 965:
Page 966 and 967:
Page 968 and 969:
Page 970 and 971:
Page 972 and 973:
Page 974 and 975:
Page 976 and 977:
Page 978 and 979:
Page 980 and 981:
Page 982 and 983:
Page 984 and 985:
Page 986 and 987:
Page 988 and 989:
Page 990 and 991:
Page 992 and 993:
Page 994 and 995:
Page 996 and 997:
Page 998 and 999:
Page 1000 and 1001:
Page 1002 and 1003:
Page 1004 and 1005:
Page 1006 and 1007:
Page 1008 and 1009:
Page 1010 and 1011:
Page 1012 and 1013:
Page 1014 and 1015:
Page 1016 and 1017:
Page 1018 and 1019:
Page 1020 and 1021:
Page 1022 and 1023:
Page 1024 and 1025:
Page 1026 and 1027:
Page 1028 and 1029:
Page 1030 and 1031:
Page 1032 and 1033:
Page 1034 and 1035:
Page 1036 and 1037:
Page 1038 and 1039:
Page 1040 and 1041:
Page 1042 and 1043:
Page 1044 and 1045:
Page 1046 and 1047:
Page 1048 and 1049:
Page 1050 and 1051:
Page 1052 and 1053:
Page 1054 and 1055:
Page 1056 and 1057:
Page 1058 and 1059:
Page 1060 and 1061:
Page 1062 and 1063:
Page 1064 and 1065:
Page 1066 and 1067:
Page 1068 and 1069:
Page 1070 and 1071:
Page 1072 and 1073:
Page 1074 and 1075:
Page 1076 and 1077:
Page 1078 and 1079:
Page 1080 and 1081:
Page 1082 and 1083:
Page 1084 and 1085:
Page 1086 and 1087:
Page 1088 and 1089:
Page 1090 and 1091:
Page 1092 and 1093:
Page 1094 and 1095:
Page 1096 and 1097:
Page 1098 and 1099:
Page 1100 and 1101:
Page 1102 and 1103:
Page 1104 and 1105:
Page 1106 and 1107:
1312A AUTHOR INDEX HEPATOLOGY, Octo
Page 1108 and 1109:
Page 1110 and 1111:
Page 1112 and 1113:
Page 1114 and 1115:
Page 1116 and 1117:
Page 1118 and 1119: 1324A AUTHOR INDEX HEPATOLOGY, Octo
Page 1160 and 1161: 1366A CATEGORY INDEX HEPATOLOGY, Oc
Page 1172: 1378A CATEGORY INDEX HEPATOLOGY, Oc
show all

studies

Create successful ePaper yourself

Delete template?

Save as template?